{"id":5302,"date":"2021-12-08T14:04:37","date_gmt":"2021-12-08T11:04:37","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5302"},"modified":"2021-12-09T14:05:35","modified_gmt":"2021-12-09T11:05:35","slug":"fda-belli-gruplarda-covid-19un-temas-oncesi-profilaksisinde-uzun-etkili-monoklonal-antikor-kullanimina-izin-verdi","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/fda-belli-gruplarda-covid-19un-temas-oncesi-profilaksisinde-uzun-etkili-monoklonal-antikor-kullanimina-izin-verdi\/","title":{"rendered":"FDA, Belli Gruplarda COVID-19\u2019un Temas \u00d6ncesi Profilaksisinde Uzun  Etkili Monoklonal Antikor Kullan\u0131m\u0131na \u0130zin Verdi"},"content":{"rendered":"<p><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-86785 alignleft\" src=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2020\/01\/FDA_.png\" alt=\"\" width=\"52\" height=\"52\" \/><strong>ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), COVID-19&#8217;un temas \u00f6ncesi profilaksisi (\u00f6nlenmesi) i\u00e7in AstraZeneca&#8217;n\u0131n Evusheld (tixagevimab cilgavimab ile birlikte paketlenmi\u015f ve birlikte uygulanan) ilac\u0131na\u00a0 belirli yeti\u015fkinlerde ve pediyatrik bireylerde (12 ya\u015f ve \u00fczeri, en az 40 kilo) uygulanmak \u00fczere acil kullan\u0131m izni (EUA) yay\u0131mlad\u0131.<\/strong><\/p>\n<p>\u015eu anda yaln\u0131zca, SARS-CoV-2 virusu bula\u015fmam\u0131\u015f ve yak\u0131n zamanda SARS-CoV-2 bula\u015fm\u0131\u015f biriyle temas etmemi\u015f bireylerde \u00fcr\u00fcn\u00fcn kullan\u0131m\u0131na izin verilmektedir. Acil kullan\u0131m izni a\u015fa\u011f\u0131da belirtilen ki\u015filer i\u00e7in verilmi\u015ftir:<\/p>\n<ul>\n<li>T\u0131bbi bir duruma ba\u011fl\u0131 olarak veya imm\u00fcnosupresif ila\u00e7lar\/tedaviler al\u0131nmas\u0131 nedeniyle ba\u011f\u0131\u015f\u0131kl\u0131k sistemi orta ila ciddi derecede\u00a0 bask\u0131lanm\u0131\u015f ve COVID-19 a\u015f\u0131s\u0131na yeterli ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturamayabilecek ki\u015filer (bu t\u00fcr t\u0131bbi durum veya tedavi \u00f6rnekleri sa\u011fl\u0131k hizmetleri sa\u011flayanlar i\u00e7in kaz\u0131rlanan bilgi sayfas\u0131nda bulunabilir) veya;<\/li>\n<li>Bir COVID-19 a\u015f\u0131s\u0131na ve\/veya bu a\u015f\u0131lar\u0131n bile\u015fenlerine kar\u015f\u0131 \u015fiddetli advers reaksiyon \u00f6yk\u00fcs\u00fc olan, bu nedenle onaylanm\u0131\u015f veya izin verilen programa g\u00f6re mevcut bir COVID-19 a\u015f\u0131s\u0131 ile a\u015f\u0131lanmas\u0131 \u00f6nerilmeyen ki\u015filer.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure\"><strong>Haber \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), COVID-19&#8217;un temas \u00f6ncesi profilaksisi (\u00f6nlenmesi) i\u00e7in AstraZeneca&#8217;n\u0131n Evusheld (tixagevimab cilgavimab ile birlikte paketlenmi\u015f ve birlikte uygulanan) ilac\u0131na\u00a0 belirli yeti\u015fkinlerde ve pediyatrik bireylerde (12 ya\u015f ve \u00fczeri, en az 40 kilo) uygulanmak \u00fczere acil kullan\u0131m izni (EUA) yay\u0131mlad\u0131. \u015eu anda yaln\u0131zca, SARS-CoV-2 virusu bula\u015fmam\u0131\u015f ve yak\u0131n zamanda SARS-CoV-2 bula\u015fm\u0131\u015f biriyle temas etmemi\u015f bireylerde \u00fcr\u00fcn\u00fcn kullan\u0131m\u0131na izin verilmektedir. Acil kullan\u0131m izni a\u015fa\u011f\u0131da belirtilen ki\u015filer i\u00e7in verilmi\u015ftir: T\u0131bbi bir duruma ba\u011fl\u0131 olarak veya imm\u00fcnosupresif ila\u00e7lar\/tedaviler al\u0131nmas\u0131 nedeniyle ba\u011f\u0131\u015f\u0131kl\u0131k sistemi orta ila ciddi derecede\u00a0 bask\u0131lanm\u0131\u015f ve COVID-19 a\u015f\u0131s\u0131na yeterli ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturamayabilecek ki\u015filer (bu t\u00fcr t\u0131bbi durum veya [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5303,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5302"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5302"}],"version-history":[{"count":1,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5302\/revisions"}],"predecessor-version":[{"id":5304,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5302\/revisions\/5304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5303"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}